Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Darzalex Faspro Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The historical period’s expansion was driven by daratumumab’s clinical effectiveness, restrictions associated with intravenous administration, an increase in multiple myeloma cases, the adoption of hospital-based oncology practices, and enhancements in patient survival rates.
The forecast period’s growth is driven by a rise in multiple myeloma diagnoses, the widening scope of outpatient oncology services, a growing demand for treatments with shorter durations, active clinical research programs, and favorable reimbursement policies. Key developments shaping this period involve a transition to subcutaneous cancer therapies, increasing use of CD38-directed agents, a focus on swift drug delivery, an expanding array of multiple myeloma treatments, and enhancements to patient ease within oncology care.
Download A Free Sample Report For Comprehensive Market Insights:
Darzalex Faspro Market Growth Factors Supporting Long-Term Expansion
The growing prevalence of cancer is set to fuel the expansion of the darzalex faspro market in the years ahead. Cancer encompasses a collection of diseases marked by uncontrolled cell proliferation and the ability to spread to various parts of the body. The increasing number of cancer cases is fueled by an aging population, unhealthy lifestyle habits, rising environmental exposures, improved diagnostic methods, and hereditary factors. Darzalex Faspro plays a key role in managing cancer by serving as a potent therapy that specifically targets and eliminates CD38-positive cells, thereby strengthening the immune system’s capacity to fight cancer, which aids in controlling and slowing the advancement of multiple myeloma and other similar malignancies. For example, in April 2024, the American Cancer Society, a professional organization based in the United States, reported that in 2022, there were 20 million new cancer diagnoses globally, along with 9.7 million cancer-related deaths. By 2050, the annual number of new cancer cases is projected to climb to 35 million. Consequently, the rising occurrence of cancer is anticipated to drive growth in the darzalex faspro market.
Darzalex Faspro Market Driver: Impact Of Global Healthcare Infrastructure Expansion On The Growth Of The Darzalex Faspro Market
The worldwide development of healthcare infrastructure is expected to propel growth in the darzalex faspro market over the coming years. Healthcare infrastructure comprises the physical and organizational frameworks, facilities, resources, and systems essential for providing medical services to a population. This global expansion is motivated by several critical factors such as the aging demographic, the rising prevalence of chronic diseases, and innovations in technology. For patients receiving darzalex faspro, strong healthcare infrastructure is vital as it ensures access to qualified medical personnel who can administer the subcutaneous injection in outpatient settings, thereby minimizing the necessity for extended hospital stays. By way of illustration, in May 2023, the American Health Care Association, a United States-based nonprofit organization, noted that the country had 6,129 hospitals, representing a 0.591% increase compared to the 6,093 hospitals recorded in the previous year. Hence, the growth of healthcare infrastructure is anticipated to support the darzalex faspro market.
Darzalex Faspro Market Segment Breakdown: Which Categories Generate The Most Revenue?
The darzalex faspro market covered in this report is segmented –
1) By Indication: Multiple Myeloma, AL Amyloidosis
2) By Route Of Administration: Oral, Parenteral, Other Route Of Administration
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channel
4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users
Darzalex Faspro Market Industry Trends Shaping Future Revenue Growth
Key industry players in the darzalex faspro market are prioritizing the expansion of regulatory approvals for combination protocols, specifically quadruplet therapy, to enhance patient outcomes and prolong survival. Quadruplet therapy involves a regimen comprising four distinct therapeutic agents that target various disease pathways to produce a synergistic effect. As an illustration, in July 2024, Johnson & Johnson Services Inc., a pharmaceutical company based in the US, secured approval from the US Food and Drug Administration (FDA) for DARZALEX FASPRO (daratumumab and hyaluronidase-fish) when used alongside bortezomib, lenalidomide, and dexamethasone (D-VRd) for both induction and consolidation treatment in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation. This regulatory nod encourages the uptake of more intensive combination strategies aimed at fostering deeper and more sustained patient responses.
Darzalex Faspro Market Key Players And Strategic Industry Positioning
Major companies operating in the darzalex faspro market are Johnson & Johnson Services Inc.
Access The Complete Darzalex Faspro Market Report:
Darzalex Faspro Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the darzalex faspro market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the darzalex faspro market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model